Abstract: The present invention relates to a method for making a copolymer comprising polymerizing the monomers in a solution comprising the monomers and a solvent, wherein the solvent comprises water and an alcohol. Furthermore, the present invention relates to the copolymer obtainable by this method (“the copolymer according to the present invention”) and to the use of the copolymer according to the present invention for styling or for fixing human hair. Furthermore, the present invention relates to the use of a more generally defined copolymer for styling or for fixing human hair, and for providing high gloss to the hair that is styled or fixed.

Abstract: Systems, methods, and devices relating to tracking a vehicle on its journey. At predetermined reporting time intervals, the vehicle's location is determined using GNSS and a current vector is calculated based on a current location and an immediately preceding location. The difference between the current vector and the immediately preceding vector is then determined and this difference is stored in the data packet. The data packet is transmitted to the base station using a two-way radio data link at select predetermined transmission time intervals. The data in the data packet is encoded to minimize the number of bits needed to store each data point.

Abstract: Various VCSEL device packages and VCSEL array configurations are disclosed. In one example, a device contains two or more VCSELs, each VCSEL having a substantially triangular body. Such device packages allow for denser VCSEL array configurations than those provided by traditional VCSEL device packages. The denser VCSEL array configurations not only allow for more VCSELs to be batch manufactured per wafer but also allow for denser layouts on various mounting surfaces.

Abstract: The invention provides a compound which is (a) a phenylamide derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate, prodrug or solvate thereof: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.

Abstract: Covalent conjugates of an ?,?-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the ?,?-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells.

Abstract: A process and apparatus for separating a feed containing hydrogen, carbon monoxide, methane, and optionally nitrogen to form a product gas having a desired H2:CO molar ratio and optionally a hydrogen product gas and a carbon monoxide product gas. The feed is partially condensed to form a hydrogen-enriched vapor fraction and a carbon monoxide-enriched liquid fraction. The hydrogen-enriched vapor fraction and carbon monoxide-enriched liquid fraction are combined in a regulated manner to form an admixture, which is cryogenically separated to form the product mixture having the desired H2:CO molar ratio.

Abstract: Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent ?C— or ?N—; W is a divalent radical —CH?CH— or CH2CH2—; R1 is an ester group; R2 is the side chain of a natural or non-natural alpha-amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.

Abstract: A turbofan engine includes a turbine engine having a rotatable fan and a generator. The generator further includes a main machine, an exciter, and a generator control unit for controlling the excitation of the main machine. A rotor assembly is located within one of the blades, and a stator assembly that is along a rotational path of the rotor assembly whereby the operation of the turbine engine rotates the fan, which rotates the rotor assembly along its rotational path past the stator assembly to generate electricity.

Abstract: The invention provides a compound which is (a) a phenylamide derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate, prodrug or solvate thereof: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.

Abstract: A drilling tool apparatus (10) comprises an elongate drilling arrangement (12) for drilling a hole in a wall and an elongate sleeve (14) mountable on the drilling arrangement. The drilling arrangement comprises an elongate shaft (18) having proximal and distal ends (18B, 18A). A cutting means (16) is provided at the distal end of the shaft for forming the hole, wherein the elongate shaft (18) is receivable through the sleeve (14).

Abstract: Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent ?C— or ?N—; W is a divalent radical —CH?CH— or CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.

Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

Abstract: An antenna architecture for hemispherically-scanning active electronically scanned arrays (AESA). The antenna architecture utilizes variable diameter disks of antenna elements configured in a conical implementation. The antenna elements are oriented such that the element boresight is normal to the surface of the conical structure. Beamforming takes place on each disk first, and them separately in combining the signals from each disk, thereby reducing complexity. The antenna optionally utilizes disks of antenna elements of the same diameter to form a cylindrical antenna, which when combined with a conical configuration create enhanced sectors while maintaining a hemispherical coverage capability. Further, use of two conical configurations can produce a fully spherical coverage capability.

Abstract: This invention is a combination stringed musical instrument like a guitar along with bass guitar elements. The invention can be either acoustic or electric. The instrument employs a common body, neck, and fingerboard, with the scale of the neck and fingerboard of a traditional guitar. The instrument uses both standard guitar and standard bass guitar strings. Significantly, this invention is designed to incorporate one or more bass strings replacing string(s) of a traditional guitar, with those bass string(s) tuned one octave lower than the string(s) replaced. An arrangement of independent electromagnetic pickups is used to isolate the signals from the bass strings from the signals of the guitar strings, and optionally present those signals as combined or separate at the output jack.

Abstract: Provided are: a copolymer for rheological or cosmetic compositions and a composition thereof, and methods of making and using the same. Said copolymer comprises a) a first acrylic ester as monomer A, said monomer A being a branched acrylic ester; b) at least one further acrylic ester as monomer B, said monomer B being a linear acrylic ester; c) a cyclic N-vinyl amide as monomer C; d) at least one compound comprising a radically polymerizable ?.?-ethylenically un-saturated double bond and at least one cationic and/or cationogenic moiety said compound being monomer D; e) at least one monoethylenically unsaturated carboxylic acid as monomer E; with the monomer B in its polymerized form having a glass transition temperature of 24° C. or lower and making at most one third of the weight amount of monomer A.

Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.

Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(?O), —S(?O)2—, —C(?O)O—, —C(O)NR3—, —C(?S)—NR3, —C(?NH)NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X2-Q1- or -Q1-X2— wherein X2 is —O—, S— or NRA— wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic r

Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.

Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.